NC-BANK-OF-AMERICA
25.1.2013 08:01:27 CET | Business Wire | Pressemeddelelse
Bank of America today announced the formation of the Bank of America Global Advisory Council with the appointment of 13 internationally recognized business, academic and public policy leaders. The Global Advisory Council will share expertise and insights on the bank’s global engagement and help it further strengthen its worldwide relationships.
Chaired by Chief Executive Officer Brian Moynihan, the Bank of America Global Advisory Council will also advise senior bank executives on trends and emerging opportunities in local markets.
“Bank of America has relationships with clients who compete in every region of the globe,” said Moynihan. “We thank our Global Advisory Council leaders for sharing their perspective, experience, and judgment, which will help make us a better partner for the clients we serve.”
Members of the Bank of America Global Advisory Council, which is a non-fiduciary body, include:
- Bader M. Al Sa’ad (Kuwait), managing director and CEO, Kuwait Investment Authority.
- Donald R. Argus AC (Australia), former CEO, National Australia Bank, and former chairman, BHP Billiton Group.
- Thierry Breton (France), chairman and CEO, Atos S.E.; director on the board of Carrefour S.A.; and former finance minister of France.
- Edson de Godoy Bueno (Brazil), president and CEO, Amil Participacões S.A., and director on the board of UnitedHealth Group.
- Chong-Suk Choi (South Korea), president and CEO, chairman of the board of directors, Korea Investment Corporation.
- The Hon. Kay Bailey Hutchison (USA), former U.S. Senator (R-Texas); former vice-chairman of the National Transportation Safety Board; and advisory board member for the Center for Strategic and International Studies.
- Sir Sam E. Jonah (Ghana), founder and chairman, Jonah Capital (Pty) Ltd.; former executive president, AngloGold Ashanti; and director on the board of Vodafone plc.
- Eijiro Katsu (Japan), former administrative vice minister at Japan’s Ministry of Finance, and former director general at Japan’s Finance Bureau.
- Dr. Jürgen Kluge (Germany), director emeritus, McKinsey & Company, Inc.; former chairman and CEO, Franz Haniel and Cie. GmbH; and director on the board of SMS GmbH.
- Ali Y. Koç (Turkey), executive board member of Koç Holding and chairman of Ford Otosan; and former group president of Corporate Communication and Information Technology, Koç Holding AS.
- Prof. Frederick Ma, GBS, JP (Hong Kong), former secretary for Financial Services and the Treasury and former secretary for Commerce and Economic Development, Hong Kong; director on the boards of Agricultural Bank of China, China Resources Land Ltd, COFCO Corporation, Husky Energy Inc., Hutchison Port Holdings Management Pte. Limited; the trustee-manager of Hutchison Port Holdings Trust; and International Advisory Council member, China Investment Corp.
- Dr. Patrick Soon-Shiong (USA), founder, former chairman and CEO, Abraxis Bioscience; founder of American Pharmaceutical Partners; managing director, California Capital Equity LLC; founder and CEO, Nantworks; and founder and chairman, Healthcare Transformation Institute.
- David Westin (USA), former president and CEO, NewsRight LLC, and former president, ABC News.
The Bank of America Global Advisory Council will hold its inaugural Annual Meeting in Hong Kong in early March.
Bank of America
Bank of America is one of the world's largest
financial institutions, serving individual consumers, small- and
middle-market businesses and large corporations with a full range of
banking, investing, asset management and other financial and risk
management products and services. The company provides unmatched
convenience in the United States, serving approximately 53 million
consumer and small business relationships with approximately 5,500
retail banking offices and approximately 16,300 ATMs and award-winning
online banking with 30 million active users. Bank of America is among
the world's leading wealth management companies and is a global leader
in corporate and investment banking and trading across a broad range of
asset classes, serving corporations, governments, institutions and
individuals around the world. Bank of America offers industry-leading
support to approximately 3 million small business owners through a suite
of innovative, easy-to-use online products and services. The company
serves clients through operations in more than 40 countries. Bank of
America Corporation stock (NYSE: BAC) is a component of the Dow Jones
Industrial Average and is listed on the New York Stock Exchange.
Visit the Bank of America newsroom for more Bank of America news .
Contact:
Reporters May Contact:
For EMEA:
John McIvor, Bank of America,
+44.020.7995.8347
john.mcivor@baml.com
Victoria
Garrod, Bank of America, +44.7738.011.500
victoria.garrod@baml.com
For
AsiaPac:
Mark Tsang, Bank of America, +852.2536.3366
mark.tsang@baml.com
For
the U.S.:
Scott Silvestri, Bank of America, +1.980.388.9921
scott.silvestri@bankofamerica.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum